N-Methanocarbathymidine

Drug Profile

N-Methanocarbathymidine

Alternative Names: N-MCT

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator N&N Pharmaceuticals
  • Class
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Herpes simplex virus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase I Herpes zoster
  • Preclinical Herpes simplex virus infections; Poxvirus infections

Most Recent Events

  • 27 Sep 2016 N-Methanocarbathymidine receives Orphan Drug status for Herpes simplex virus infections (In neonates) in USA
  • 20 Apr 2016 Phase-I clinical trials in Herpes zoster (In volunteers) in USA (PO)
  • 01 Apr 2016 Preclinical trials in Herpes simplex virus infections in USA (PO) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top